The objective of this study was to assess the safety and to make a
preliminary assessment of the efficacy of 0.5 96 ferric hyaluronate adhesion
prevention gel in reducing the incidence, severity, and extent of adhesion
formation at sites without direct surgical trauma or adhesiolysis at
the time of surgical laparotomy. A second look laparoscopy was performed
to assess the adhesions. Twenty seven patients aged 24-41 years
received 300 ml 0.5 % ferric hyaluronate adhesion prevention gel or lactated
Ringer's solution as an intraperitonea1 irtstillate at the completion of
the laparotorrty procedure. A planned second- look laparoscopy, 8-12
weeks after the laparotomy was performed to evaluate the presence of
adhesions. AU patients tolerated the procedure and did not mantfest any
serious adverse events. There was one patient developed minor intestinal
leak that closed' spontaneously after 3 weeks. At second look laparoscopg,
patients treated with 0.5 % fenic hyaLurortate adhesion prevention gel
had significantly fewer adhesions than control patients. When adhesions
did form, they ,were significantly Less extensive and less severe in patients
who received 0.5 96 ferric hyaluronate adhesion prevention gel. In
conclusion 0.5 % femc hyaluronate adhesion prevention solution was
sore and highly efficacious in reduction of the number, severity, and ex- |
